Neuraminidase A controls pneumococcal recognition and fate: deficiency enhances immune sensing and intracellular survival, while treatment promotes phagocytic clearance [0.03%]
Kristine Farmen,Georgia Yfanti,Fabienne Geers et al.
Kristine Farmen et al.
Streptococcus pneumoniae (pneumococcus) is a leading cause of bacterial meningitis worldwide and is associated with cerebrovascular complications and long-term neurological sequelae. These outcomes are largely driven by an excessive yet ine...
PD-1 inhibitor-induced rheumatic, endocrine, and sarcoidosis-like immune-related adverse events in metastatic melanoma are associated with improved survival and lower corticosteroid exposure [0.03%]
抗PD-1诱导的类风湿、内分泌和肉芽肿性疾病样的免疫相关不良事件与转移性黑色素瘤改善的生存及较低的皮质类固醇暴露相关
Maria Lindén,Hifaa Al Remawi,Anna Fager et al.
Maria Lindén et al.
Introduction: Programmed cell death protein 1 (PD-1) inhibitors improve survival in advanced melanoma but can induce immune-related adverse events (irAEs). IrAEs have been linked to better outcomes. However, it remains un...
Comprehensive spatial and immune profiling of metastatic mismatch repair-deficient colorectal cancer reveals response to immunotherapy [0.03%]
全面的空间和免疫谱分析揭示了错配修复缺陷型转移性结直肠癌对免疫疗法的反应
Ilkyu Park,Hari Kang,Se-Hee Kim et al.
Ilkyu Park et al.
Introduction: Mismatch repair-deficient (dMMR) colorectal cancers (CRCs) exhibit variable clinical responses to immune checkpoint inhibitors (ICIs) despite their high immunogenicity. ...
Targeting intratumoral regulatory T cells by CD137 aptamer-shRNA chimeras [0.03%]
利用CD137适配体-shRNA嵌合分子靶向肿瘤内调节性T细胞
Kang Yi Lee,Yu Mei,Haiyan Liu et al.
Kang Yi Lee et al.
Introduction: The cytokine CD137 (TNFRSF9, 4-1BB) is best known as a T cell costimulatory molecule. However, CD137 is also part of a negative feedback mechanism that limits T cell activation, and that is employed by regul...
Sarah Danson,Robert P Jones,Kristina Duggleby et al.
Sarah Danson et al.
Cancer vaccines offer transformative potential in oncology, especially with advances in mRNA technologies. To accelerate advances in cancer vaccine research and capitalize on its COVID-19 vaccine leadership, the UK Government has launched t...
Preclinical assessment of MAGE-A4-specific TCR-NK cells against solid tumors [0.03%]
抗实体瘤MAGE-A4特异性TCR-NK细胞的临床前评估
Margherita Boieri,Justyna Kmiecik,Maja Sandve et al.
Margherita Boieri et al.
T cell (Tc) receptor (TCR)-based cell therapies have shown clinical efficacy across many cancer types and represent an attractive strategy for targeting solid tumors. However, the immunosuppressive tumor microenvironment, downregulation of ...
Targeted 19F MRI for molecular imaging of the immune response and its theranostics [0.03%]
用于免疫反应及其诊疗的19F磁共振成像分子影像学研究
Pascal Bouvain,Sebastian Temme,Ulrich Flögel
Pascal Bouvain
The in vivo visualization of inflammatory processes offers not only the possibility of localizing disease but also of monitoring its progression over time. Among available imaging modalities, combined 1H/19F MRI has emerged as a powerful te...
[89Zr]Zr-DFO-avelumab accumulation in resectable non-small cell lung carcinoma indicates a suppressive tumor microenvironment amendable to neoadjuvant avelumab treatment [0.03%]
89Zr标记的DFO-avelumab在可切除非小细胞肺癌中的聚集表明了一个有利于新辅助avelumab治疗的免疫抑制性肿瘤微环境
Sarah R Verhoeff,Evelien A J van Genugten,Iris A E van der Hoorn et al.
Sarah R Verhoeff et al.
Background: Immune checkpoint inhibitor treatment in non-small cell lung cancer (NSCLC) expands to early stages of disease. The neoadjuvant setting allows to investigate the mechanism-of-action of immune therapy using mol...
A phase 1 experimental medicine study of anti-CD3 monoclonal antibody in rheumatoid arthritis [0.03%]
抗CD3单克隆抗体治疗类风湿性关节炎的I期试验性药物研究
Catherine A Lawson,Rachel Harry,Bridget Griffiths et al.
Catherine A Lawson et al.
Introduction: An Fc-mutated chimeric aglycosyl anti-CD3 monoclonal antibody (mAb), otelixizumab, has been used successfully to treat renal transplant rejection and type 1 diabetes, with reduced toxicity compared with trad...
Callum Blee,Munitta Muthana,Greg Wells et al.
Callum Blee et al.
Cancer vaccines and oncolytic viruses (OVs) represent promising immunotherapeutic strategies, harnessing adaptive and innate immune responses for targeted tumour eradication. Cancer vaccines aim to induce tumour-specific cytotoxic T lymphoc...